Clinical Trials Browser

NCT06120283 2026-04-15

BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors

Phase 1 Recruiting

399 enrolled

BreastThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT07198724 2026-04-09

ERADICATE

Phase 1/2 Recruiting

65 enrolled

Breast

Breast Neoplasms

NCT05386108 2026-04-06

ELECTRA

Phase 1/2 Recruiting

73 enrolled

BreastCNS

Brain Diseases, Brain Neoplasms, Breast Diseases, Breast Neoplasms, Central Nervous System Diseases, Neoplasms, Neoplasms by Site, Central Nervous System Neoplasms

Clinical Trials

BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors

ERADICATE

ELECTRA

Phase Ib/II Trial of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to HR+/Her2- Breast Cancer

ELEGANT

Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer

COMBINE-01

CAPELA

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

ELEVATE

Immunologic Targeting of ESR1 Receptor for Hormone Receptor Expressing Metastatic Breast Cancer

ELEMENT

POP-ELA

ADAPTela

Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer

EMERALD

TREAT ctDNA

ELCIN

SOLTI-2104

ELONA

A Rollover Protocol of Elacestrant, in Combination With Onapristone, for Patients With ER+, PR+, HER2- Advanced or Metastatic Breast Cancer

ELIPSE

Phase IB Study to Evaluate RAD1901 on the Availability of Estrogen Receptor Binding Sites in Metastatic Breast Cancer